openPR Logo
Press release

Rubella Testing Market Global Industry Research 2024

01-04-2017 06:08 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Rubella Testing Market: Overview 

Rubella or German measles is a serious condition (disease) caused by the infection of rubivirus (genus). Sometimes rubella when passed from pregnant mother to her baby then it is termed as congenital rubella. Rubella is a contagious disease and can spread through air or close contact between patient and a healthy individual. Signs and symptom of rubella include fever, headache, inflammation of the eyes and muscle or joint pain.

Culture test (nasal or throat swab culture) and blood test to check the function of immune system are the major tests performed for the detection of rubella. Women who are pregnant must undergo rubella test to know the functioning of immune system against rubella virus. There remains chance of miscarriage or stillbirth for those pregnant mothers who are suffering from measles as the child may be born with birth defects.

Presently there is no treatment option available in the market for the treatment of rubella. Patients are prescribed acetaminophen for reduction of rubella fever. Rubella can be prevented with the utilization of measles-mumps-rubella (MMR) vaccine. Rubella vaccine is recommended for all children and is routinely given when children are 12 months to 15 months old. Almost everyone who receives the vaccine has immunity to rubella for his lifetime.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2935

The global market for rubella testing is being driven primarily due to increasing awareness among people and advancement in diagnostic test. Moreover, government initiatives and support also accounted for the growth of the global rubella testing market. Pregnant mother who are suffering from rubella and are unaware about the high risk of passing the disease from her to unborn baby also contributes significantly in the market growth.

Centre for Disease Control and Prevention (CDC) stated that more than 100,000 infants are born with congenital rubella syndrome (CRS) annually worldwide. World Health Organization (WHO) revealed that in 1996, the number of countries that have incorporated rubella-containing vaccines into their routine national immunization program was 83. Later in 2011, the number was increased to 130 for the incorporation of rubella-containing vaccines into their routine national immunization.

Rubella Testing Market: Region-wise Outlook

North America dominates the global market for rubella testing due to strong demand of diagnostic test in this region. Moreover increasing awareness among people and initiative taken by the federal government also accounted for the market growth in North American region. Europe represents the second position in the global rubella testing market due to increasing awareness among people and extensive government initiative taken by the European government. For an instance, in October 2010, WHO Region of the America and Europe has established rubella elimination and CRS prevention goals for the year 2010 and 2015.

Asia - Pacific is considered as an untapped market due to lack of awareness among people about rubella testing. Asian market growth will be fuelled by the presence of untapped opportunities due to extensive increase in the healthcare infrastructure and growing market penetration in this region.

Rubella Testing Market: Key Players

Major market players contributing in the global market share of rubella testing market includes Abbott Laboratories, Inc., Becton, Dickinson and Company, Biomerica, Inc., bioMerieux, Inc., Novartis Diagnostics, Johnson & Johnson Diagnostics, Inc., Olympus Corporation, Qiagen N.V., Siemens AG, Thermo Fischer Scientific, Inc., and Zenith Healthcare Ltd.    

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse Full Research Report on Rubella Testing Market:
http://www.transparencymarketresearch.com/rubella-diagnostic-testing-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rubella Testing Market Global Industry Research 2024 here

News-ID: 404952 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Rubella

Rubella Vaccine Comprehensive study explores Huge Growth by 2028
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘Rubella Vaccine: Global Opportunity Analysis and Industry Forecast 2020-2028’. This market research study determines the increase in changes and the aspects which are likely to have an impact on the growth of the Rubella Vaccine. Increased demand for the technologies is also one of the factors, which are likely to boost the growth of this industry. The market research study uses
The Rubella Treatment market to invigorate from 2020 to 2030
Rubella is the contagious viral infection of the respiratory system. Rubella is also known as German measles. Rubella is not similar to measles, although they have similar characteristics such as red rushes, but they are caused by a different virus. Rubella virus causes joint pain, low-grade fever, sore throat and skin rash. About 25% to 50% of people infected with rubella virus do not experience any symptoms. Rubella virus spreads
Rubella Diagnostic Testing Market Analysis with Research Report 2020
Global Rubella Diagnostic Testing Market - Growth, Trends, And Forecast (2020 - 2024) The report presents an in-depth assessment of the Global Rubella Diagnostic Testing including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Global Rubella Diagnostic Testing investments from 2020 till 2024. The Global Rubella Diagnostic Testing market
Measles, Mumps and Rubella (MMR) Vaccines Market Opportunity Analysis, 2026 – …
Measles, mumps, and rubella are the three common contagious airborne diseases that are highly caused by virus transmitted by sneezing and coughing of the infected person, which could lead to serious complications or death among children. Vaccines of these diseases are sold as attenuated viral vaccines, manufactured in a lyophilised formulation, which requires reconstitution with water for injection diluent and are available in two forms i.e. monovalent as well as
Rubella Testing Market to Observe Strong Development by 2024
Rubella or German measles is a serious condition (disease) caused by the infection of rubivirus (genus). Sometimes rubella when passed from pregnant mother to her baby then it is termed as congenital rubella. Rubella is a contagious disease and can spread through air or close contact between patient and a healthy individual. Signs and symptom of rubella include fever, headache, inflammation of the eyes and muscle or joint pain. Culture test
Rubella Testing Market - Positive long-term growth outlook 2016 - 2024
Rubella or German measles is a serious condition (disease) caused by the infection of rubivirus (genus). Sometimes rubella when passed from pregnant mother to her baby then it is termed as congenital rubella. Rubella is a contagious disease and can spread through air or close contact between patient and a healthy individual. Signs and symptom of rubella include fever, headache, inflammation of the eyes and muscle or joint pain. Culture